Core Scientific, Inc. (CORZ)

NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-10-23

$13.10-0.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Core Scientific, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-23.2% · beyond scale

+10% or more+5%0%−5%−10% or less

0.28 → 0.21 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	208.72M
EPS	—	-0.042
Annual ending 2026-12-31
Revenue	—	682.61M
EPS	—	-4.412
Annual ending 2027-12-31
Revenue	—	1.14B
EPS	—	0.215

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage $3.3 billion debt offering and improve financial stability	Core Scientific is a leader in AI infrastructure with a $3.3 billion debt offering supporting capital allocation.	Intact	Debt levels increase materially or financial stability worsens	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS improves from -$1.04 in 2026 to positive $0.30 in 2027	A primary condition in Core Scientific, Inc.'s published investment case. The stated target is EPS >= $0.30.	Broken	EPS remains negative or below $0.30 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth at or above -8% next year	A primary condition in Core Scientific, Inc.'s published investment case. The stated target is >= -8% YoY.	Broken	YoY revenue growth falls below -8% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.21

$0.44 → $0.21 · observed estimates

FY2027 revenue$1.14B

$1.11B → $1.14B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.44	$1,106,054,612	6 / 11
2026-07-25	$0.44	$1,106,054,612	6 / 11
2026-07-26	$0.44	$1,106,054,612	6 / 11
2026-07-27	$0.44	$1,106,054,612	6 / 11
2026-07-28	$0.44	$1,106,054,612	6 / 11
2026-07-29	$0.53	$1,111,692,020	5 / 10
2026-07-30	$0.38	$1,137,400,965	6 / 10
2026-07-31	$0.31	$1,161,123,743	6 / 11
2026-08-01	$0.31	$1,161,123,743	6 / 11
2026-08-02	Unavailable	$1,161,545,560	2 / 16
2026-08-03	$0.31	$1,161,123,743	6 / 11
2026-08-04	Unavailable	$1,161,545,560	2 / 16
2026-08-05	Unavailable	$1,153,251,810	3 / 16
2026-08-06	$0.30	$1,155,529,967	6 / 11
2026-08-07	$0.30	$1,155,529,967	6 / 11
2026-08-08	Unavailable	$1,153,251,810	3 / 16
2026-08-09	Unavailable	$1,153,251,810	3 / 16
2026-08-10	$0.30	$1,155,529,967	6 / 11
2026-08-11	Unavailable	$1,153,251,810	3 / 16
2026-08-12	$0.30	$1,155,529,967	6 / 11
2026-08-13	Unavailable	$1,153,251,810	3 / 16
2026-08-14	$0.30	$1,155,529,967	6 / 11
2026-08-15	$0.30	$1,155,529,967	7 / 11
2026-08-16	$0.30	$1,155,529,967	7 / 11
2026-08-17	$0.30	$1,155,529,967	7 / 11
2026-08-18	$0.30	$1,155,529,967	7 / 11
2026-08-19	$0.30	$1,155,529,967	7 / 11
2026-08-20	$0.30	$1,155,529,967	7 / 11
2026-08-21	$0.30	$1,155,529,967	7 / 11
2026-08-22	$0.30	$1,155,529,967	7 / 11
2026-08-23	$0.30	$1,155,529,967	7 / 11
2026-08-24	$0.30	$1,155,529,967	7 / 11
2026-08-25	$0.30	$1,155,529,967	7 / 11
2026-08-26	$0.30	$1,155,529,967	7 / 11
2026-08-27	$0.30	$1,155,529,967	7 / 11
2026-08-28	$0.30	$1,155,529,967	7 / 11
2026-08-29	$0.30	$1,155,529,967	7 / 11
2026-08-30	$0.30	$1,155,529,967	7 / 11
2026-08-31	$0.30	$1,155,529,967	7 / 11
2026-09-01	$0.30	$1,155,529,967	7 / 11
2026-09-02	$0.30	$1,155,529,967	7 / 11
2026-09-03	$0.30	$1,155,529,967	7 / 11
2026-09-04	$0.30	$1,155,529,967	7 / 11
2026-09-05	$0.30	$1,139,090,553	7 / 11
2026-09-06	$0.30	$1,139,090,553	7 / 11
2026-09-07	$0.30	$1,139,090,553	7 / 11
2026-09-08	$0.30	$1,139,090,553	7 / 11
2026-09-09	$0.30	$1,139,090,553	7 / 11
2026-09-10	$0.30	$1,139,090,553	7 / 11
2026-09-11	$0.30	$1,139,088,200	7 / 11
2026-09-12	$0.30	$1,139,088,200	7 / 11
2026-09-13	$0.30	$1,139,088,200	7 / 11
2026-09-14	$0.30	$1,139,088,200	7 / 11
2026-09-15	$0.30	$1,139,088,200	7 / 11
2026-09-16	$0.30	$1,139,088,200	7 / 11
2026-09-17	$0.30	$1,139,088,200	7 / 11
2026-09-18	$0.30	$1,139,088,200	7 / 11
2026-09-19	$0.28	$1,134,544,411	7 / 11
2026-09-20	$0.28	$1,134,544,411	7 / 12
2026-09-21	$0.28	$1,134,544,411	7 / 12
2026-09-22	$0.28	$1,137,963,760	7 / 12
2026-09-23	$0.28	$1,137,963,760	7 / 12
2026-09-24	$0.28	$1,148,619,466	8 / 13
2026-09-25	$0.28	$1,148,619,466	8 / 13
2026-09-26	$0.28	$1,148,619,466	8 / 13
2026-09-27	$0.27	$1,141,261,396	8 / 14
2026-09-28	$0.27	$1,141,261,396	8 / 14
2026-09-29	$0.27	$1,141,261,396	8 / 14
2026-09-30	$0.27	$1,141,261,396	8 / 14
2026-10-01	$0.26	$1,137,123,301	8 / 14
2026-10-02	$0.26	$1,137,122,863	8 / 14
2026-10-03	$0.26	$1,137,122,863	8 / 14
2026-10-04	$0.26	$1,137,122,863	8 / 14
2026-10-05	$0.26	$1,137,122,863	8 / 14
2026-10-06	$0.26	$1,137,122,863	8 / 14
2026-10-07	$0.26	$1,137,122,863	8 / 14
2026-10-08	$0.26	$1,137,122,863	8 / 14
2026-10-09	$0.26	$1,137,122,863	8 / 14
2026-10-10	$0.26	$1,137,122,863	8 / 14
2026-10-11	$0.26	$1,137,122,863	8 / 14
2026-10-12	$0.26	$1,137,122,863	8 / 14
2026-10-13	$0.26	$1,137,122,863	8 / 14
2026-10-14	$0.26	$1,137,122,863	8 / 14
2026-10-15	$0.26	$1,137,132,387	8 / 14
2026-10-16	$0.26	$1,137,134,254	8 / 14
2026-10-17	$0.26	$1,137,134,254	8 / 14
2026-10-18	$0.21	$1,137,134,254	8 / 14
2026-10-19	$0.21	$1,137,134,254	8 / 14
2026-10-20	$0.21	$1,137,134,254	8 / 14
2026-10-21	$0.21	$1,137,134,254	8 / 14
2026-10-22	$0.21	$1,137,134,254	8 / 14
2026-10-23	$0.21	$1,137,134,254	8 / 14
2026-10-24	$0.21	$1,137,134,254	8 / 14

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	16	1
2026-06-01	16	2
2026-07-01	16	2
2026-08-01	16	1
2026-09-01	20	2
2026-10-01	20	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 20 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage $3.3 billion debt offering and improve financial stabilityDirect metric needs a verified mapping
EPS improves from -$1.04 in 2026 to positive $0.30 in 2027Published status: Broken
Revenue growth at or above -8% next yearPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-55.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Core Scientific, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making growth and transition story, not a proven durable compounder. The long-term thesis is on watch: management is making progress on colocation, but recent financial performance is weak and earnings quality is fragile.

What's priced into Core Scientific, Inc.

CORZ carries a durable premium versus peers, while the expectations gap is negative, meaning expectations appear demanding relative to the evidence. The model has low confidence, and the priced-in assessment describes the premium as justified rather than driven by a full stack of fragility factors.

What the fundamentals likely do

Near-term execution remains uncertain, with consecutive earnings misses and a 53% estimated miss probability ahead of the next report. Colocation revenue has grown sharply, and management has expanded power capacity through acquisitions, but mining revenue has declined as the business shifts toward colocation; acquisition progress is mixed.

What Core Scientific, Inc. hinges on

Over the multi-year view, the key test is whether expanded power capacity and repurposed mining facilities support sustained colocation growth. Near-term conditions may also depend on interest-rate cuts and whether major technology companies continue to report strong results and raise guidance; weaker results or guidance would remove a sector tailwind.